#5-87E. Bridging the Gap: Tailoring Myopericarditis Management in Autoimmune Diseases (Lancet Rheumatol, 2026)

How applicable are generic cardiology guidelines when managing myopericardial disease in systemic autoimmune rheumatic diseases? While the 2025 ESC guidelines address autoimmune etiologies, this viewpoint emphasizes that chronic background inflammation compromises the accuracy of standard biomarkers and cardiac MRI criteria, whereas current management guidance relies heavily on limited evidence derived from small, heterogeneous observational cohorts. Recognizing these diagnostic and therapeutic pitfalls urges physicians to avoid one-size-fits-all approaches and establish collaborative rheumatology-cardiology care pathways to optimize patient outcomes.

Citation: Plein S, Youngstein T, Weber B, Buch MH. Relevance of the 2025 ESC guidelines for the diagnosis and management of myocarditis and pericarditis for systemic autoimmune rheumatic diseases. Lancet Rheumatol. 2026.

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.